G&C Medical Technology Expands Manufacturing Capacity By 40%

G&C Medical Technology has completed a major investment in its integrated manufacturing facilities, increasing total output capacity by 40% across all three product categories.

The expansion adds significant production and distribution capability to support growing demand from distributors, hospital purchasing networks, and OEM partners. It also shortens lead times on fast-moving surgical and PPE lines — a direct response to partner feedback.

What the expansion delivers

The upgraded footprint introduces additional production lines, expanded warehousing, and enhanced quality-control infrastructure, all maintained under the same certified standards that define the G&C portfolio.

• Higher throughput across O.R., critical care, and PPE categories
• Shorter, more predictable lead times for forecasted lines
• Expanded capacity for OEM and private-label production runs
• Continued ISO 13485, CE, FDA, and MDR compliance throughout

Built around partner demand

The decision to expand followed sustained growth in partner volumes and a clear signal that reliability of supply remains the single most important factor for healthcare buyers.

Reliability of supply is the foundation of every partnership we build — this investment is about protecting that promise as we grow.

— G&C Leadership

With facilities now spanning two continents under the company's dual-site US–China strategy, G&C is positioned to manufacture closer to its primary markets while navigating dual-regulatory landscapes with agility.

The expanded capacity is operational now, with partners already seeing improved availability across the catalog.